A previous study showed that proteasomal inhibitors significantly enhance the growth inhibition of drugs targeting DNA topoisomerase II, indicating that blocking TOP2 degradation is an attractive strategy to sensitize cancer cells to TOP2-targeting chemotherapeutic drugs (TOP2 poisons)35. The gene discussed is TOP2A; the disease is cancer.